Blocking PINK1 Triggers Explosive Cancer Cell Death in Neuroblastoma

Neuroblastoma is one of the most common and deadly pediatric solid tumors, and current therapies frequently fail high-risk patients. The mitochondria-protective kinase PINK1 is known for initiating mitophagy — the selective removal of damaged mitochondria — thereby limiting the accumulation of harmful reactive oxygen species (ROS). This study asked whether deliberately inhibiting PINK1 could be exploited to kill neuroblastoma cells by flooding them with mitochondrial ROS and triggering pyroptosis, a lytic, pro-inflammatory programmed cell death modality increasingly recognized as a potent anti-tumor mechanism.

The research team used multiple complementary approaches in neuroblastoma cell lines (SK-N-SH and SH-SY5Y): pharmacological inhibition of PINK1 with AC220 (quizartinib, an FDA-approved FLT3 inhibitor repurposed here), CRISPR-Cas9 knockout of PINK1, and shRNA-mediated knockdown. Mitophagy was assessed using the mitochondria-targeted monomeric keima-red (mtKeima) reporter, mitochondrial ROS was quantified with MitoSOX staining, and cell death was characterized by LDH release, propidium iodide uptake, ANXA5/PI flow cytometry, and western blotting for GSDME cleavage. Mouse xenograft models were used for in vivo validation with ethacrynic acid (EA) co-treatment.

The core mechanistic finding was a linear signaling cascade: PINK1 inhibition → impaired mitophagy → elevated mitochondrial ROS → oxidation and oligomerization of the outer mitochondrial membrane protein TOMM20 → mitochondrial recruitment and activation of BAX → CYCS (cytochrome c) release into the cytosol → CASP3 activation → GSDME cleavage → pyroptosis. Crucially, blocking ROS with the antioxidant NAC, or inhibiting caspase-3 with Q-VD-OPH, completely abolished pyroptosis, confirming the ROS-CASP3-GSDME axis as the primary mechanism. GSDMD, the canonical pyroptosis effector, was not involved.

AC220 treatment dose-dependently suppressed PINK1 kinase activity, reduced mitophagy flux (measured by mtKeima ratio shifts and p62/SQSTM1 accumulation), and raised mitochondrial ROS levels significantly above untreated controls. PINK1 knockout cells showed a nearly identical phenotype, ruling out off-target effects of AC220. The combination of AC220 with ethacrynic acid — a clinical diuretic with known ROS-inducing properties — produced synergistic tumor cell killing in vitro and markedly reduced xenograft tumor growth in vivo compared to either agent alone, without apparent systemic toxicity in the mouse models.

From a broader perspective, these findings reframe PINK1 not merely as a neuroprotective kinase relevant to Parkinson's disease, but as a critical survival factor in neuroblastoma that shields tumor cells from ROS-driven death. By converting the normally pro-survival mitophagy pathway into a vulnerability, the study presents a tractable two-drug strategy — PINK1 inhibitor plus ROS inducer — that could be clinically testable given that AC220 is already approved and EA has clinical history. Caveats include the use of two established cell lines without patient-derived organoids, reliance on xenograft rather than immunocompetent models, and the need for PINK1 expression profiling across neuroblastoma subtypes to identify which patients would most benefit.